

Presentation and Chairman's address to the 2023 Annual General Meeting

2 November 2023

4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) attaches the following materials to be presented at the Annual General Meeting of Shareholders to be held today at 10.00am AEDT:

1. Script of the prepared address to be given by the Chairman; and
2. Presentation slides to accompany the meeting.

–ENDS–

Authorised by the 4DMedical Company Secretary.

Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Naomi Lawrie

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



4DMedical Limited
Annual General Meeting
Chairman's Address
10.00AM, Thursday, 2 November 2023

Good morning Shareholders and fellow Directors,

Welcome to the Annual General Meeting of 4DMedical for the 2022-23 Financial Year.

Today we are gathered on the traditional lands of the Wurundjeri peoples of the Kulin nation, and I pay my respects to their elders past, present and emerging.

As we have a quorum, I formally declare the meeting open.

Today we are presenting from the Woodward Centre, within Melbourne University, the hub of a thriving research and innovation precinct that drives the medtech sector. The sector continues to grow and recover from a post COVID environment with life returning to normal as students and workers alike return to the vibrant precinct.

We consider ourselves fortunate to be associated with such an esteemed institution and sector.

FY2023 Overview

To begin with I would like to express my sincere thanks to our investors, both institutional and retail, who have supported the Company throughout the year and especially with the recent capital raise.

Access to capital is a constant challenge for companies such as ours, particularly in these uncertain times, and the success of the raise conducted in May reflects the commitment and confidence that our shareholders have in our mission to improve respiratory healthcare and deliver on our commercialisation strategy.

FY2023 has been a year of significant progress, with advances across all areas of operations.

Focusing on the US, this year we announced commercialisation advances with quality partners such as the University of Miami, the U.S. Department of Veterans Affairs, and the U.S. Department of Defense.

Firstly, I would like to reflect on the opportunity that the VA presents. A vision to enable better care for Veterans is core to 4DMedical's mission, and the Company is uniquely positioned to make a significant contribution to this cause.

Early in the financial year, the Company released data from the Vanderbilt 'burn pit' trial showing XV Technology could detect the presence of constrictive bronchiolitis (CB) in Veterans exposed to burn pits and other harmful toxins while on deployment, and where conventional pulmonary function tests and CT scans failed to do so. The \$280 billion PACT Act requires the VHA to provide toxic exposure screening to each of the nine million Veterans enrolled in the VA health care program, and data from a clinical trial at Vanderbilt University positions XV Technology as a non-invasive and scalable solution.

Building on from this, the Company is seeing growing momentum in its commercialisation with the VA. You will recall that we recently completed our first commercial XV LVAS scan at Harry S. Truman Memorial Veterans Hospital, one of 171 major clinical centres within the Veterans Health Administration (VHA). The



scan represented a major step forward in demonstrating our ability to deliver an XV LVAS scan in a routine VA hospital clinical setting.

Closely following this achievement, we were granted 'Authority to Operate' at the Harry S. Truman Memorial Veterans Hospital, which allows us to deliver scans at scale through our fully automated SaaS platform at that site. The team are working closely with other VA sites for a second Authority to Operate, which would then allow the Company to be awarded a national ATO covering the entire VA network.

In respect of the Department of Defense, 4DMedical also has an opportunity to inform the treatment of active military personnel afflicted by respiratory disease and initiated a commercial pilot within the Military Health System (MHS) of the U.S. Department of Defense in May. Whilst the scale of the project is not material, it represents a significant milestone in the commercialisation strategy.

Finally, the 5 year SaaS agreement with the University of Miami enables the Company to deliver XV LVAS ventilation reports, and follows the success of a long-term clinical trial program already underway at Miami and validates the efficacy and utility of XV Technology®.

Turning our attention to the financial performance of the Company, I would like to report that 4DMedical had a cash position of \$69.6 million as at 30 June 2023. The Company's balance sheet remains healthy following the successful capital raise enabling pursuit of its strategic objectives.

Total Income for FY2023 was \$13.9 million, comprising operating revenue of \$0.7 million and other income of \$13.2 million. Notably, cash receipts from customers were \$2.2 million, up 413% from FY2022, while operating cash outflows were \$22.7 million, a reduction of \$2.6 million on last year.

Finally operating expenditure for FY2023 was \$45.3 million, while net operating expenditure (allowing for R&D tax incentives of \$5.5 million and the Medical Research Future Fund grant instalment of \$7.7 million) was \$32.1 million, reflecting the Company's go-to-market efforts in the U.S. gained momentum and the industry recovery from the impact of COVID-19.

Corporate Governance

Throughout FY23, 4DMedical continued to mature as a listed entity, actively enhancing governance structures to foster a culture of integrity, promote strong alignment with the interests of shareholders, employees and other stakeholders, and promote accountability and transparency for sustainable value creation.

I thank my fellow Directors for their continuing contribution to the company's governance.

I would particularly like to acknowledge Ms Evonne Collier who has recently resigned. Evonne has made a significant contribution to 4DMedical since joining the Board, including serving in the role as Chair of the Remuneration and Nomination Committee. On behalf of the Board of 4DMedical, I would like to sincerely thank Evonne for her contributions to the Company.

I would also like to welcome Dr Geraldine McGinty to our meeting today as an addition to our board, bringing particular expertise in the U.S. health system and the nuances of reimbursement in that market.

Today is my final AGM as I have decided not to seek re-election at this meeting. I leave the company in a strong position, poised to deliver on its commercialisation objectives.



During my tenure, it has transitioned from start up to IPO to the productive organisation it has become – benefitting from the application of key governance principles and oversight without detriment to a culture of innovation and a capability to translate research into valuable clinical practices.

I wish you all individually and the company collectively the very best wishes for a bright future.



The future of lung health

4DMedical Limited (ASX:4DX)
Annual General Meeting
2 November 2023

4DMedical Limited ABN 31 161 684 831



Disclaimer

This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (**Company** or **4DMedical**). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (**Group**) and their activities current as of 2 November 2023 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities.

This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase securities and does not include any application form for securities. This presentation does not constitute an advertisement for an offer or proposed offer of securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The securities in the Company (**Securities**) have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States.

Overview



Agenda

1. Opening & introductions
2. Chairman's address
3. CEO address
4. Procedural matters
5. Formal business
6. Closing remarks

Board of Directors

Significant medical and commercial sector experience



BRUCE RATHIE
Non-Executive Chairman
(outgoing)

Experienced lawyer, Investment Banker and Company Director; currently Non-Executive Director of PolyNovo Limited (ASX:PNV), Cettire Limited (ASX:CTT), Capricorn Mutual Limited and Capricorn Society Limited, and Chairman of CleanSpace Holdings Limited (ASX:CSX).



Dr ANDREAS FOURAS PhD
Managing Director and CEO

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



LIL BIANCHI
Non-Executive Chair
(incoming Chair)

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.



Dr ROBERT A. FIGLIN MD
Non-Executive Director

Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai.



Dr GERALDINE MCGINTY MD
Non-Executive Director

Internationally recognized expert in health care strategy and imaging economics, and prominent advocate for patient-centered care. A Professor of Radiology and Population Health Sciences at Weill Cornell Medicine in New York City, she serves as Senior Associate Dean for Clinical Affairs.



JULIAN SUTTON
Non-Executive Director

Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London.



JOHN LIVINGSTON
Executive Director

Founding partner of ASX listed Integral Diagnostics (ASX:IDT) and an industry leader in the implementation of PACS and RIS in radiological settings.

Key advisors

Medical experts



Dr SAM HUPERT MBBS
Advisory Board Member

Co-founder and Chief Executive Officer of Pro Medicus Ltd (ASX:PME) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and Australia.



Prof BRUCE THOMPSON PhD
Advisory Board Member

Board Member and Past President of the Thoracic Society of Australia and New Zealand; currently Dean of the School of Health Sciences at the University of Melbourne, and a former Head of Physiology Services at the Alfred Hospital.



Dr DAVID J. SHULKIN MD
Key Advisor

Highly respected physician and health care executive, Dr Shulkin was previously the Secretary of the United States Department of Veterans Affairs (VA). As Secretary of the VA, Dr Shulkin oversaw the US government's second largest agency, with over 350,000 employees and 1,700 facilities, serving over 9 million Veterans.

Chairman's address



BRUCE RATHIE
Non-Executive Chairman

Experienced lawyer, investment banker and company director.



FY23 financial summary

- 4DMedical reported a net cash balance of \$69.6 million at 30 June 2023, with zero debt.
- Total income is \$13.9 million, up 3.7%, comprising \$0.7 million in operating revenue and \$13.2 million in other income.
- Total operating expenditure \$45.3 million, up 22%, driven by higher employee benefits expenses, investment in research and development and its 'go to market' capabilities to support commercialisation.

\$69.6m

Cash reserves

\$0.7m

Sales and maintenance revenue

\$13.9m

Total income

\$45.3m

Operating expenditure

131 employees

Our people

(\$31.6m)

Net income

Chief Executive Officer



Dr ANDREAS FOURAS PhD
Managing Director

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.





“4DMedical has all the advantages and none of the disadvantages of existing lung diagnostic technology.

Our XV Technology[®] and Lung Ventilation Analysis Software (XV LVAS[®]) is the latest evolution.

The opportunities are significant.”

Professor Andreas Fouras

Founder, Inventor

Managing Director & Chief Executive Officer


4DMedical Limited (ASX:4DX)

XV Technology® advantages




New medical insights

Functional insight of
spirometry at a regional level



Improved safety

Comparable radiation
dose to X-ray



Superior results

High-detail resolution
of a CT scan



Patient outcomes

Improved clinical
outcomes



Time efficient

Faster, more efficient
testing using existing
hardware



Low cost

Competitive pricing
below incumbent
technologies

XV Technology® & Lung Ventilation Analysis Software (XV LVAS®)

XV LVAS® is the world's first and only modality which can dynamically quantify ventilation throughout the lungs, exposing patients to lower levels of radiation relative to other diagnostic methods.



XV Technology® 4D view of lung performance

FY23 achievements

1H FY2023

Commercialisation	Early-stage commercialisation in Australia Expanded relationship with Australia's I-MED Radiology Network	June 2022
Clinical validation	Burn pit trial validates XV Technology® Burn pit clinical trial conducted by US-based Vanderbilt University Medical Center indicates XV Technology® is a superior way to detect constrictive bronchiolitis	August 2022
Regulatory	XV LVAS® technology gets its own CPT code US Current Procedural Terminology (CPT) Editorial Panel creates new Category III CPT code to uniquely identify the use of XV LVAS® technology; provides pathway to reimbursement	October 2022
Product expansion	CT LVAS™ technology's Australian release CT LVAS™ technology released in Australia, adding to 4DMedical's product offering	October 2022
Government funding	4DMedical receives a further MRFF payment A further \$9.4 million (ex GST) received from Australian Government's Medical Research Future Fund after meeting product development milestones	November 2022
Product expansion	XV Scanner at RSNA 2023 Display of XV Scanner at RSNA annual conference, world's largest gathering of medical imaging professionals	November 2022



FY23 achievements

2H FY2023

Commercialisation	Signing of first US hospital SaaS contract 5-year contract signed with the University of Miami to provide XV LVAS® ventilation reports, its first US hospital SaaS contract	April 2023
Commercialisation	Dr David Shulkin joins 4DMedical Former U.S. Secretary of Veterans Affairs, Dr Shulkin joins 4DMedical in an advisory capacity to provide critical support and advice	April 2023
Commercialisation	First US VA scan completed The first commercial XV LVAS® scan completed within the US Veterans Health Administration, conducted at Harry S. Truman Memorial Veterans Hospital in Missouri	May 2023
Commercialisation	First commercial pilot at U.S. Department of Defense 4DMedical wins first commercial pilot at the Military Health System within the U.S. Department of Defense	May 2023
Commercialisation	Authority to Operate granted at major US VA hospital 4DMedical granted Authority to Operate at Harry S. Truman Memorial Veterans Hospital	May 2023
Product expansion	CT:VQ development milestones met 4DMedical's CT:VQ progresses to a developmental stage, opening the way for the release of early clinical data	May 2023
Capital raise	Successful equity raisings to accelerate commercialisation 4DMedical completes successful equity raising and Securities Purchase Plan, raising an additional \$45m in new capital	May 2023



FY24 achievements to date

1H FY2024

Government funding

4DMedical wins \$1.1m CTCM funding

Funding enables expansion of XV Scanner capability beyond ventilation into perfusion

July 2023

Leadership and expertise

Appointment of Geraldine McGinty to Board

Appointment of Geraldine McGinty provides critical U.S. healthcare system and processes required in enabling healthcare providers to receive payment from insurance companies

September 2023

Commercialisation

Expansion in ANZ

Commercial collaboration advanced with imaging partner I-MED Radiology Network
Established imaging partnerships in South Australia, Western Australia, and metropolitan Sydney
Ongoing refinement of I-MED model with substantive improvements in patient booking process

October 2023



FY24 target catalysts

Commercialisation

- VA funded trial
- 2nd Authority to Operate awarded enabling National Authority to Operate
- Extend Department of Defense engagement
- Execution of commercial agreement with US based academic medical center
- Expansion in ANZ

Clinical

- Commencement of trials for CT:VQ
- Commencement of XV Scanner trials
- Publication of peer reviewed journals

Regulatory


- FDA submissions for XV Scanner and CT:VQ
 - Funding and budget appropriation for PACT Act
-



Investment opportunity

	Global demand	• The demand for sophisticated respiratory diagnostics solutions is growing • Diagnostic technology largely unchanged for ~50 years • Lung diagnostics market ripe for disruption
	Global commercialisation strategy	• Commercialisation driven by clinical utilisation demonstrating medical necessity • Clinical trials well advanced across multiple conditions provide evidence of efficacy and utility • Commercial pilots build use case and support reimbursement • Long term agreements with hospital & radiology networks
	Near term commercialisation opportunity	• Immediate priority to drive adoption with VA in US and ANZ radiology networks • VA scan conducted at Harry S. Truman Memorial; target funded multi-site pilot • Integration with VA with Authority to Operate • 4DMedical approved provider for VA; PACT Act \$280 billion • ANZ market rollout progressing, target adjacent markets
	Medium to long term commercialisation	• Reimbursement in US for XV Technology® • CPT Category III code from 1 July 2023; establish pathway for payment • Product pipeline strong – perfusion capability in development • FDA Submissions for CT:VQ and XV Scanner FY2024
	Organisational maturity	• Organisational capability, strong intellectual property, and funding for next stage of growth • Key appointments to drive commercialisation • Strong controls on IP with 71 patents, providing defendable moat • Well funded for growth

Commercialisation strategy



Research partners delivering the body of scientific evidence for clinical use

Peer reviewed publications of clinical trial results



Physicians gaining familiarity with technology and business case for clinical adoption


Reimbursement – coding, coverage, and payment



Long term agreements with hospital networks and radiology providers

**Accessibility & availability for diagnosis;
Improved productivity & costs for hospitals**

Software offering & applications



Commercialisation strategy – clinical trial validation



BLVR University of Miami XV LVAS®	Asthma Cleveland Clinic XV LVAS®	Paediatric CF John Hopkins XV LVAS®	Lung Transplant Alfred Hospital, Melbourne XV LVAS®	ILD-WLL Prince Charles Hospital XV LVAS®
PH Cleveland Clinic VQ	COPD Vanderbilt University XV LVAS®	BLVR Temple University XV LVAS®	COPD University of Miami XV LVAS®	CF Women and Children Hospital Adelaide XV LVAS®
Lung Transplant Duke University XV LVAS®	CB (PDRS) Vanderbilt University XV LVAS®	COPD Oregon Health & Science University XV LVAS®		
COPD John Hopkins XV LVAS®	Pneumonitis Cedar Sinai XV LVAS®			


The importance of reimbursement to achieve commercialisation

- The publication of clinical trials is critical to 4DMedical's ability to secure reimbursement and achieve commercialisation
- Clinical trials establish *a medical necessity* for use in diagnosis and treatment of respiratory illnesses


4DMedical's clinical trial validation process

- 4DMedical's XV Technology® continues to be validated through application and clinical utility in peer-reviewed journals and conferences
- 4DMedical currently has four submissions under review, with eight in preparation

Procedural matters



Formal business



Items of Business

Item 1: Financial Report, Directors' Report and Auditors Report

Item 2: Remuneration Report

Item 3: Election of Director, Dr Geraldine McGinty

Item 4: *Withdrawn*

Item 5: Re-election of Director, Ms Lilian Bianchi

Item 6: Grant of Options to the Managing Director and CEO

Item 7: Amendments to the Constitution

Formal business

Item 1: Financial Report, Directors' Report and Auditors Report

To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2023.

Formal business

Item 2: Remuneration report

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2023, is adopted.”

In Favour	Against	Proxy Discretion	Abstain
11,194,251	2,229,960	3,189,538	211,870
67.38%	13.42%	19.20%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 2.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Formal business

Item 3: Election of Director, Dr Geraldine McGinty

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of clause 13.1 of the Company’s constitution, ASX Listing Rule 14.4, and for all other purposes, Dr Geraldine McGinty, a non-executive director appointed on 25 September 2023, and being eligible, is re-elected as a director.”

In Favour	Against	Proxy Discretion	Abstain
80,613,255	294,668	3,189,538	14,613
95.86%	0.35%	3.79%	

Further Information:

- The Board (other than Dr Geraldine McGinty) recommends that Shareholders vote in favour of Item 3.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.

Formal business

Item 4: Re-election of Director, Mr Bruce Rathie

Withdrawn

Formal business

Item 5: Re-election of Director, Ms Lilian Bianchi

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of clause 13.3 of the Company’s constitution, ASX Listing Rule 14.5, and for all other purposes, Ms Lilian Bianchi, a non-executive director appointed on 11 December 2019, and being eligible, is re-elected as a director.”

In Favour	Against	Proxy Discretion	Abstain
80,510,810	383,557	3,189,768	27,939
95.75%	0.46%	3.79%	

Further Information:

- The Board (other than Ms Lilian Bianchi) recommends that Shareholders vote in favour of Item 5.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.

Formal business

Item 6: Grant of Options to the Managing Director and CEO

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of ASX Listing Rule 10.4, sections 200B and 200E of the Corporations Act and for all other purposes, the grant of up to 1,306,100 options to Managing Director and CEO, Dr Andreas Fouras, under the 4DMedical Long Term Incentive Plan and on the terms described in the explanatory statement accompanying this notice, is approved.”

In Favour	Against	Proxy Discretion	Abstain
14,703,192	1,048,888	3,290,358	220,359
77.21%	5.51%	17.28%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 6.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.



Formal business

Item 7: Amendments to Constitution

To consider, and if thought fit, to pass, the following as a **special** resolution:


“That, for the purposes of section 136(2) of the Corporations Act 2001 (Cth) and for all other purposes, the Members of the Company approve the amendments, to permit the holding of wholly virtual meetings to the extent permitted under the Corporations Act, of the Company’s Constitution as set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
78,709,082	1,932,316	3,196,198	274,478
93.88%	2.30%	3.81%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 7.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.

Poll





4D Medical Limited (ASX:4DX)

Annual General Meeting

2 November 2023

Copyright ©4D Medical Limited 2023

Level 7, Melbourne Connect

700 Swanston Street

Melbourne, Victoria 3053

Australia

www.4dmedical.com

ABN 31 161 684 831

